SYRE · ISSUER CIK 1636282
Spyre Therapeutics, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 4 Spyre Therapeutics, Inc. insiders reported $0.00 of open-market purchases and $16.9M of sales on SEC Form 4.
↗4 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 9 of 9 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$16.9MInsider selling
−$16.9MNet open-market
Oct 2, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 2, 202621:30 | Oct 1, 2026 | SYRE | See Remarks | S · Sell10b5-1 | $91.03 | −28,933 | 2,845 | -91% | −$2.6M | ||
| Oct 2, 202621:30 | Oct 1, 2026 | SYRE | See Remarks | M · Exercise10b5-1 | $14.50 | +28,933 | 31,778 | +1017% | $420K | ||
| Oct 2, 202621:29 | Oct 1, 2026 | SYRE | Chief Executive Officer, Director | S · Sell10b5-1 | $92.01 | −15,000 | 537,540 | -3% | −$1.4M | ||
| Oct 2, 202621:29 | Oct 1, 2026from Sep 30, 2026 | SYRE | Chief Financial Officer | S · Sell10b5-1 | $90.47 | −25,000 | 79,762 | -24% | −$2.3M | ||
| Oct 2, 202621:29 | Oct 1, 2026from Sep 30, 2026 | SYRE | Chief Financial Officer | M · Exercise10b5-1 | $14.50 | +25,000 | 87,262 | +40% | $363K | ||
| Sep 3, 202621:34 | Sep 2, 2026from Sep 1, 2026 | SYRE | See Remarks | S · Sell10b5-1 | $87.35 | −28,399 | 2,845 | -91% | −$2.5M | ||
| Sep 3, 202621:34 | Sep 2, 2026from Sep 1, 2026 | SYRE | See Remarks | M · Exercise10b5-1 | $14.50 | +28,399 | 3,245 | — | $412K | ||
| Sep 3, 202621:33 | Sep 2, 2026from Sep 1, 2026 | SYRE | Chief Financial Officer | S · Sell10b5-1 | $88.75 | −25,732 | 79,762 | -24% | −$2.3M | ||
| Sep 3, 202621:33 | Sep 1, 2026 | SYRE | Chief Financial Officer | M · Exercise10b5-1 | $14.50 | +7,500 | 105,494 | +8% | $109K | ||
| Sep 3, 202621:33 | Sep 1, 2026 | SYRE | Chief Executive Officer, Director | S · Sell10b5-1 | $87.29 | −15,000 | 552,540 | -3% | −$1.3M | ||
| Aug 10, 202621:31 | Aug 7, 2026 | SYRE | Director | S · Sell10b5-1 | $104.53 | −23,000 | 0 | -100% | −$2.4M | ||
| Aug 10, 202621:31 | Aug 7, 2026 | SYRE | Director | M · Exercise10b5-1 | $10.39 | +5,000 | 5,000 | New | $52K | ||
| Aug 5, 202621:32 | Aug 3, 2026 | SYRE | Chief Financial Officer | S · Sell10b5-1 | $95.57 | −7,500 | 97,994 | -7% | −$717K | ||
| Aug 5, 202621:32 | Aug 3, 2026 | SYRE | Chief Financial Officer | M · Exercise10b5-1 | $14.50 | +7,500 | 105,494 | +8% | $109K | ||
| Aug 5, 202621:31 | Aug 3, 2026 | SYRE | Chief Executive Officer, Director | S · Sell10b5-1 | $95.51 | −15,000 | 567,540 | -3% | −$1.4M |